Wen Jimmy, Syed Burhaan, Kim Solomon, Shehabat Mouhamad, Ansari Ubaid, Razick Daniel I, Akhtar Muzammil, Pai David
Physical Medicine and Rehabilitation, California Northstate University College of Medicine, Elk Grove, USA.
Surgery, California Northstate University College of Medicine, Elk Grove, USA.
Cureus. 2024 Aug 1;16(8):e65961. doi: 10.7759/cureus.65961. eCollection 2024 Aug.
Nicotinamide adenine dinucleotide (NAD+) is essential in the proper function of many essential cellular processes in the human body. The purpose of this review is to investigate the effect of nicotinamide mononucleotide (NMN), a NAD+ precursor, on physical performance and evaluate the safety profile of supplementation. A systematic review search criteria following the guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was performed in four databases for randomized controlled trials on NMN supplementation. Study variables included title, author, publication date, study year, number of patients, dosage, mean age, mean follow-up time, pre- and post-intervention reported outcomes, and rates of complications. Ten studies, including 437 patients, with a mean age of 58.0 years (35.1 to 81.1 years) and a mean follow-up time of 9.6 weeks (4 to 12 weeks) were included in this study. NMN dosages ranged from 150 to 1200 mg/day. Mean pre-intervention grip strength (two studies) and skeletal mass index (two studies) were 29.9 kilograms (kg) (range: 21.4-40.1 kg) and 7.4 kg/m (range: 6.9-7.65 kg/m), respectively. Mean post-intervention grip strength and skeletal mass index were 30.5 kg (range: 21.7-41.9 kg) and 7.4 kg/m (6.8-7.64 kg/m), respectively. There were no serious adverse effects observed. Moreover, of the reported side effects, they were determined to be independent of NMN supplementation. Therefore, patients taking NMN supplementation demonstrated non-significantly improved physical performance parameters. NMN is well tolerated with no serious adverse effects observed.
烟酰胺腺嘌呤二核苷酸（NAD+）对人体许多基本细胞过程的正常功能至关重要。本综述的目的是研究NAD+前体烟酰胺单核苷酸（NMN）对身体机能的影响，并评估补充NMN的安全性。按照系统评价与Meta分析优先报告条目（PRISMA）指南的系统评价检索标准，在四个数据库中对关于补充NMN的随机对照试验进行了检索。研究变量包括标题、作者、出版日期、研究年份、患者数量、剂量、平均年龄、平均随访时间、干预前后报告的结果以及并发症发生率。本研究纳入了10项研究，共437例患者，平均年龄58.0岁（35.1至81.1岁），平均随访时间9.6周（4至12周）。NMN剂量范围为150至1200毫克/天。干预前平均握力（两项研究）和骨骼肌质量指数（两项研究）分别为29.9千克（kg）（范围：21.4 - 40.1 kg）和7.4 kg/m（范围：6.9 - 7.65 kg/m）。干预后平均握力和骨骼肌质量指数分别为30.5 kg（范围：21.7 - 41.9 kg）和7.4 kg/m（6.8 - 7.64 kg/m）。未观察到严重不良反应。此外，在报告的副作用中，确定它们与补充NMN无关。因此，服用NMN补充剂的患者身体机能参数有非显著性改善。NMN耐受性良好，未观察到严重不良反应。
